Erythropoietin

Medikine Initiates First Clinical Trial of its Lead Program, an Interleukin-7 Mimetic, Under Management Team with Expertise in Next-Generation Cytokine Drug Discovery and Development

Retrieved on: 
Tuesday, July 19, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, IL-7, Half-life, Memory, Pharmacology, Biology, Erythropoietin, Thrombopoietin, Disease, Acquisition, Cancer, Innovation, Infection, Science, Degenerative disease, Pharmacokinetics, Safety, Therapy, Engineering, Eli Lilly and Company, Drug discovery, Technology, CD8, Saṃsāra, Sanofi, Maintenance, Bristol Myers Squibb, Human, Survival, Amgen, Cytokine, Research, Board, Health, DRS, CD4, NK, ADAS, TSCM, Clinical trial, Pharmaceutical industry, Vaccine

IL-7 is a cytokine critical for the development and maintenance of T cells, including enhancing generation, function, and survival of memory T cells.

Key Points: 
  • IL-7 is a cytokine critical for the development and maintenance of T cells, including enhancing generation, function, and survival of memory T cells.
  • The company plans to investigate MDK-703 in solid tumors following the completion of the Phase 1 clinical trial in healthy volunteers.
  • Dr. Milla commented, With its versatile drug discovery platform, Medikine is well-positioned to develop transformative therapies for cancer and other serious diseases.
  • In addition to its lead product candidate, MDK-703, Medikine also has identified novel PEPTIKINES that activate the IL-2/15 receptor complex.

Biosimilars Market to Reach $143.6 Bn, Globally, by 2031 at 24.7% CAGR: Allied Market Research

Retrieved on: 
Thursday, July 7, 2022
Monoclonality, Erythropoietin, Blood, Human, COVID-19, Growth, Growth hormone, Cancer, Industry, Degenerative disease, Prevalence, Hematologic disease, Insulin, CAGR, Vaccine, Fine chemical

PORTLAND, Ore., July 7, 2022 /PRNewswire/ -- Allied Market Research published a report, titled, "Biosimilars Market by Type (Human growth hormone, Erythropoietin, Monoclonal antibodies, Insulin, Granulocyte-Colony Stimulating Factor, Others), by Application (Blood disorders, Oncology diseases, Chronic and autoimmune diseases, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031." According to the report, the global biosimilars industry was estimated at $15.9 billion in 2021, and is anticipated to hit $143.6 billion by 2031, registering a CAGR of 24.7% from 2022 to 2031.

Key Points: 
  • "According to the report, the global biosimilars industry was estimated at $15.9 billion in 2021, and is anticipated to hit $143.6 billion by 2031, registering a CAGR of 24.7% from 2022 to 2031.
  • Increase in incidences of diabetesand autoimmune diseases drives the growth of the global biosimilars market.
  • The COVID-19 pandemic created difficulties for the pharmaceutical industry to focus on R&D activities including biosimilar development, which impacted the global biosimilars market negatively.
  • Based on region, Europe held the major share in 2021, generating nearly two-fifths of the global biosimilars market.

Biosimilars Market to Reach $143.6 Bn, Globally, by 2031 at 24.7% CAGR: Allied Market Research

Retrieved on: 
Thursday, July 7, 2022
Monoclonality, Erythropoietin, Blood, Human, COVID-19, Growth, Growth hormone, Cancer, Industry, Degenerative disease, Prevalence, Hematologic disease, Insulin, CAGR, Vaccine, Fine chemical

PORTLAND, Ore., July 7, 2022 /PRNewswire/ -- Allied Market Research published a report, titled, "Biosimilars Market by Type (Human growth hormone, Erythropoietin, Monoclonal antibodies, Insulin, Granulocyte-Colony Stimulating Factor, Others), by Application (Blood disorders, Oncology diseases, Chronic and autoimmune diseases, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031." According to the report, the global biosimilars industry was estimated at $15.9 billion in 2021, and is anticipated to hit $143.6 billion by 2031, registering a CAGR of 24.7% from 2022 to 2031.

Key Points: 
  • "According to the report, the global biosimilars industry was estimated at $15.9 billion in 2021, and is anticipated to hit $143.6 billion by 2031, registering a CAGR of 24.7% from 2022 to 2031.
  • Increase in incidences of diabetesand autoimmune diseases drives the growth of the global biosimilars market.
  • The COVID-19 pandemic created difficulties for the pharmaceutical industry to focus on R&D activities including biosimilar development, which impacted the global biosimilars market negatively.
  • Based on region, Europe held the major share in 2021, generating nearly two-fifths of the global biosimilars market.

Akebia Therapeutics Regaining Rights to Vadadustat in the United States, Europe, China and Access Consortium Countries upon Termination of Collaboration and License Agreements with Otsuka

Retrieved on: 
Thursday, June 30, 2022
Anemia, Erythropoietin, Review, FDA, Patient, European Medicines Agency, EPO, Adult, New Drug Application, Tissue, Dialysis, Endpoint security, Workforce, Mitsubishi Tanabe Pharma, MAA, Marketing, COVID-19, Company, Goal, Altitude, Mortality, Vadadustat, EMA, United Kingdom, Food, Oxygen, Lists of diseases, Dizziness, Fatigue, Chronic kidney disease, Nasdaq, Quality of life, Health, CKD, Risk, Kidney disease, Disease, Vifor Pharma, AKBA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, Pharmaceutical industry, Fine chemical, Akebia

As part of the termination, Otsuka has agreed to pay Akebia a settlement fee of $55 million.

Key Points: 
  • As part of the termination, Otsuka has agreed to pay Akebia a settlement fee of $55 million.
  • "Otsuka has been a strong partner for many years, and we appreciate their desire to have an efficient transfer of the responsibilities back to Akebia.
  • Otsuka and Akebia will coordinate to transfer the MAA to Akebia through processes outlined by the EMA.
  • Vadadustat is also under review in the United Kingdom, Switzerland, and Australia through the Access Consortium.

Global Therapeutic Proteins Market Research Report 2022: Focus on Insulin; Fusion Protein; Erythropoietin; Interferon; Human Growth Hormone; Follicle Stimulating Hormone - ResearchAndMarkets.com

Retrieved on: 
Friday, June 17, 2022
Health, Other Health, Antibody, Eli Lilly and Company, Protein engineering, CHO, FDA, CHMP, Ipilimumab, Patent, Safety, Belimumab, CDER, Vaccine, Technology, Committee for Medicinal Products for Human Use, Function, MEPS, Liver, Lists of diseases, AbbVie, Erythropoietin, Hormone, Genetic engineering, Albiglutide, Insulin, Company, Center for Drug Evaluation and Research, Cancer, Haemophilia, Infection, Growth, IX, DNA, BLA, Degenerative disease, Committee, Acquisition, Lilly, Advanced Therapy Medicinal Product, Growth hormone, Application, Anemia, Blood, Diabetes, Biosimilar, Pharmaceutical industry, Research, Adalimumab, EU

The "Therapeutic Proteins Global Market Report 2022: By Product, By Application, By Function" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Therapeutic Proteins Global Market Report 2022: By Product, By Application, By Function" report has been added to ResearchAndMarkets.com's offering.
  • The therapeutic proteins market consists of sales of therapeutic proteins.
  • The main types of products in therapeutic proteins are insulin, fusion protein, erythropoietin, interferon, human growth hormone and follicle stimulating hormone.
  • Increasing biosimilar drugs in global market decline the growth of the therapeutic proteins market.

FDA grants Orphan Drug Designation for tasquinimod in myelofibrosis

Retrieved on: 
Wednesday, May 18, 2022
Ruxolitinib, Multiple myeloma, Death, Risk, Fever, Lymphatic system, Spleen, MC, Justicia oncodes, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Infection, Survival, Erasmus, Incidence, Bone marrow failure, Nasdaq, Patient, Erasmus MC, EU, NASDAQ, MF, Acute leukemia, Erythropoietin, Therapy, Degenerative disease, Trial of the century, Research, FDA, Haematopoietic system, JAK, Partnership, Laquinimod, Fibrosis, Biotechnology, III, Anemia, CET, ACTI, CFO, Pancreatic serous cystadenoma, CEO, Pharmaceutical industry

Lund May 18, 2022 - Active Biotech AB (Nasdaq Stockholm: ACTI) today announced that the U.S. Food and Drug Administration (FDA) has granted tasquinimod Orphan Drug Designation for the treatment of myelofibrosis.

Key Points: 
  • Lund May 18, 2022 - Active Biotech AB (Nasdaq Stockholm: ACTI) today announced that the U.S. Food and Drug Administration (FDA) has granted tasquinimod Orphan Drug Designation for the treatment of myelofibrosis.
  • The Orphan Drug Designation awarded by the FDA for tasquinimod in myelofibrosis represents an important step forward for Active Biotech, said Heln Tuvesson, CEO Active Biotech.
  • The FDA Orphan Drug Designation program provides orphan status to drugs and biologics which are defined as those intended for the safe and effective treatment, diagnoses or prevention of rare diseases or disorders that affects fewer than 200,000 people in the U.S.
  • Active Biotech and Erasmus MC have initiated a research collaboration with tasquinimod in myelofibrosis, that includes preclinical studies as well as a clinical proof of concept study in patients with myelofibrosis.

FibroGen Reports First Quarter 2022 Financial Results

Retrieved on: 
Monday, May 9, 2022
European Economic Area, Interim, Safety, CTGF, LAPC, Annual report, Dialysis, SEC, JDE, CIA, Mission statement, Pamrevlumab, CKD, NASDAQ, Idiopathic pulmonary fibrosis, Company, Erythropoietin, Patient, Risk, Research, SAN, Biology, U.S. Securities and Exchange Commission, Investment, Telephone, Security (finance), Commonwealth, Erythropoiesis, IPF, NRDL, Sale, MDS, DMD, Growth, GLOBE, Chronic kidney disease, Pancreatic cancer, Microdeletion syndrome, Duchenne, Review, Webcast, Anemia, Therapy, Duchenne muscular dystrophy, Adult, Marketing, NDD, HIF, AstraZeneca, Video game, Pharmaceutical industry, Aluminium, Food delivery, Roxadustat, EEA, EU, Astellas Pharma, Roxadustat

1Q 2022 revenue of $60.8M, growth of 58% vs. 1Q 2021

Key Points: 
  • 1Q 2022 revenue of $60.8M, growth of 58% vs. 1Q 2021
    SAN FRANCISCO, May 09, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the first quarter 2022 and provided an update on the companys recent developments.
  • First quarter total roxadustat net sales in China1 by FibroGen and the distribution entity (JDE) jointly owned by FibroGen and AstraZeneca was $43.5 million, flat as compared to the first quarter of 2021.
  • Total revenue for the first quarter of 2022 was $60.8 million, as compared to $38.4 million for the first quarter of 2021.
  • To participate in the conference call by telephone, please dial 1 (877) 658-9081 (U.S. and Canada) or 1 (602) 563-8732 (international), reference the FibroGen first quarter 2022 financial results conference call, and use confirmation number 2487763.

Dr. Nidal Huniti joins A2PG as President

Retrieved on: 
Tuesday, May 3, 2022
Board, MIDD, Drug development, Decision-making, Data management, Population, Solution, University, Regeneron Pharmaceuticals, NDA, BLA, Associate, ANN, Industry, Erythropoietin, Simulation, McKesson Corporation, Science, Physiology, Principal, AstraZeneca, Army Science Board, Executive director, Pharmaceutical industry, Management, Asphalt, EU, Pharmacokinetics, Pharmacy

ANN ARBOR, Mich., May 3, 2022 /PRNewswire/ --A2PG and Amador Bioscience announced today that Dr. Nidal Huniti has joined the company as President of A2PG.

Key Points: 
  • ANN ARBOR, Mich., May 3, 2022 /PRNewswire/ --A2PG and Amador Bioscience announced today that Dr. Nidal Huniti has joined the company as President of A2PG.
  • Dr. Huniti, a veteran of the pharmaceutical industry, will report directly to A2PG CEO and Amador CSO Dr.
  • "Joining A2PG and Amador is a wonderful, exciting opportunity," Dr. Huniti said.
  • "I've known Dr. Huniti for a long time, and I can't wait for him to join us at A2PG and Amador," said A2PG CEO and Amador CSO Dr.

Biopharmaceuticals Market Global Opportunity Analysis by Product and by Application to 2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 5, 2022
Biotechnology, Pharmaceutical, Health, Industry, CAGR, Obesity, Population, USD, Conditional sentence, Urbanization, Lists of diseases, Degenerative disease, Investment, D, Erythropoietin, Growth, Merck & Co., Geography, Bacteria, CVD, Vaccine, Epidemic, Row, Biogen, Application, Amgen, Cancer, Cardiovascular disease, Immunity, Prevalence, AstraZeneca, Injection, Government, Johnson & Johnson, Review, Infection, Diabetes, Abbott Laboratories, Ageing, Insulin, Market segmentation, Novo Nordisk, Lilly, Fine chemical, Pfizer, Merck

The "Biopharmaceuticals Market by Product and by Application - Global Opportunity Analysis and Industry Forecast 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Biopharmaceuticals Market by Product and by Application - Global Opportunity Analysis and Industry Forecast 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • The biopharmaceuticals market was valued at USD 345.84 billion in 2021 and is predicted to reach USD 974.48 billion by 2030 with a CAGR of 11.7% from 2022-2030.
  • Market Segmentations and Scope of the Study:
    The biopharmaceuticals market is segmented on the basis of product, application, and geography.
  • These market players are adopting various strategies such as agreement, joint venture, and product innovations across various regions to maintain their dominance in the biopharmaceuticals market.

Akebia Therapeutics Receives Complete Response Letter from the FDA for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients

Retrieved on: 
Wednesday, March 30, 2022
Chronic kidney disease, Risk, CRL, Therapy, Vadadustat, Hepatotoxicity, Lists of diseases, Vifor Pharma, MAA, LIVE, Dialysis, Investor, Marketing, Erythropoietin, Mortality, European Medicines Agency, Adult, EPO, Dizziness, Kidney disease, Health, Food, Tissue, Oxygen, Private Securities Litigation Reform Act, Anemia, New Drug Application, Quality of life, Safety, Review, U.S. Securities and Exchange Commission, Altitude, Goal, Nasdaq, CKD, COVID-19, Regulation of tobacco by the U.S. Food and Drug Administration, Disease, NDA, Annual report, FDA, MACE, Fatigue, AKBA, Patient, Video game, Pharmaceutical industry, Medical device, Akebia

CAMBRIDGE, Mass., March 30, 2022 /PRNewswire/ --  Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) to Akebia's New Drug Application (NDA) for vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor under review for the treatment of anemia due to chronic kidney disease (CKD). The FDA issues a CRL to indicate that the review cycle for an application is complete and that the application is not ready for approval in its present form.

Key Points: 
  • Akebia will discuss the details of the CRL with its collaboration partners and request a meeting with the FDA.
  • In Japan, vadadustat is approved as a treatment for anemia due to CKD in both dialysis-dependent and non-dialysis dependent adult patients.
  • On March 29, 2022, the FDA issued a complete response letter to Akebia's New Drug Application for vadadustat for the treatment of anemia due to chronic kidney disease (CKD).
  • In Japan, vadadustat is approved as a treatment for anemia due to CKD in both dialysis-dependent and non-dialysis dependent adult patients.